William Blair Investment Management LLC Makes New $27.93 Million Investment in ICU Medical, Inc. $ICUI

Key Points

• William Blair Investment Management LLC has invested approximately $27.93 million in ICU Medical, purchasing around 211,339 shares during the second quarter.
• Recent analyst ratings reflect a mixed outlook for ICU Medical, with upgrades from some brokerages to a "buy" rating, while others maintain a "sell" rating, resulting in a consensus rating of "Moderate Buy."
• ICU Medical's CEO, Vivek Jain, increased his stake in the company by purchasing 21,929 shares, highlighting strong insider confidence in the company's future.

William Blair Investment Management LLC bought a new position in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 211,339 shares of the medical instruments supplier's stock, valued at approximately $27,928,000. William Blair Investment Management LLC owned approximately 0.86% of ICU Medical at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC raised its holdings in shares of ICU Medical by 27.2% in the 1st quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier's stock worth $99,000 after purchasing an additional 153 shares in the last quarter. Vontobel Holding Ltd. acquired a new position in ICU Medical in the 1st quarter valued at approximately $235,000. EP Wealth Advisors LLC acquired a new position in ICU Medical in the 1st quarter valued at approximately $479,000. Vident Advisory LLC bought a new stake in ICU Medical in the first quarter worth approximately $270,000. Finally, Envestnet Asset Management Inc. grew its position in ICU Medical by 8.2% in the first quarter. Envestnet Asset Management Inc. now owns 20,269 shares of the medical instruments supplier's stock worth $2,815,000 after acquiring an additional 1,534 shares in the last quarter. 96.10% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ICUI. Wall Street Zen upgraded shares of ICU Medical from a "hold" rating to a "buy" rating in a research note on Friday, September 5th. Weiss Ratings reiterated a "sell (d-)" rating on shares of ICU Medical in a research note on Wednesday, October 8th. Piper Sandler increased their price objective on shares of ICU Medical from $145.00 to $153.00 and gave the company an "overweight" rating in a research note on Wednesday, September 10th. Finally, Raymond James Financial dropped their price objective on shares of ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating for the company in a research note on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $181.00.

ICU Medical Stock Performance

ICU Medical stock opened at $118.46 on Monday. The company has a current ratio of 2.44, a quick ratio of 1.17 and a debt-to-equity ratio of 0.63. ICU Medical, Inc. has a 1 year low of $107.00 and a 1 year high of $196.26. The company has a market cap of $2.92 billion, a PE ratio of -77.93 and a beta of 0.83. The company's 50-day moving average is $123.45 and its two-hundred day moving average is $129.91.

ICU Medical (NASDAQ:ICUI - Get Free Report) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.44 by $0.66. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The company had revenue of $543.57 million for the quarter, compared to the consensus estimate of $543.33 million. During the same period in the prior year, the company posted $1.56 EPS. The company's revenue was down 8.0% compared to the same quarter last year. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. Equities analysts anticipate that ICU Medical, Inc. will post 4.11 earnings per share for the current year.

Insider Transactions at ICU Medical

In other ICU Medical news, CEO Vivek Jain bought 21,929 shares of the business's stock in a transaction on Thursday, August 14th. The shares were bought at an average cost of $112.84 per share, for a total transaction of $2,474,468.36. Following the transaction, the chief executive officer owned 130,149 shares in the company, valued at approximately $14,686,013.16. This trade represents a 20.26% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director David C. Greenberg purchased 1,200 shares of the business's stock in a transaction that occurred on Wednesday, August 27th. The stock was purchased at an average price of $126.42 per share, for a total transaction of $151,704.00. Following the completion of the transaction, the director directly owned 7,960 shares in the company, valued at $1,006,303.20. This trade represents a 17.75% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 1.50% of the company's stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

Want to see what other hedge funds are holding ICUI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ICU Medical, Inc. (NASDAQ:ICUI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.